VIATRIS INC. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
VIATRIS INC. (VTRS) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $33.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2026-08-06
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2026-06-30 was $33.00M.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2026-03-31 was $39.70M.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2025-09-30 was $26.40M.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2025-06-30 was -$300.50M, a 561.60% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was $390.80M, a 18.41% decline from fiscal 2021.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $479.00M.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was -$325.80M, a 527.00% decline from fiscal 2019.
- VIATRIS INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was $76.30M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.00M 10-Q · filed 2026-08-06 | $72.70M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $39.70M 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $26.40M 10-Q · filed 2025-11-06 | -$274.10M derived: sum of 2 quarters · filed 2026-08-06 | -$424.40M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$300.50M 10-Q · filed 2026-08-06 | -$450.80M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$150.30M 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | -$223.10M 10-Q · filed 2025-11-06 | -$158.00M derived: sum of 2 quarters · filed 2025-11-06 | -$1.80M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $65.10M 10-Q · filed 2025-08-07 | $221.30M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $156.20M 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | $162.80M 10-Q · filed 2024-11-07 | $184.20M derived: sum of 2 quarters · filed 2024-11-07 | $142.50M 10-Q · filed 2024-11-07 | -$290.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $21.40M 10-Q · filed 2024-08-08 | -$20.30M 10-Q · filed 2024-08-08 | -$452.80M derived: sum of 3 quarters · filed 2024-08-08 | -$125.50M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$41.70M 10-Q · filed 2024-05-09 | -$474.20M derived: sum of 2 quarters · filed 2024-05-09 | -$146.90M derived: sum of 3 quarters · filed 2024-05-09 | $184.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$432.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$105.20M derived: sum of 2 quarters · filed 2023-02-27 | $225.70M derived: sum of 3 quarters · filed 2023-08-07 | $390.80M 10-K · filed 2023-02-27 |
| 2022-09-30 | $327.30M 10-Q · filed 2022-11-07 | $658.20M derived: sum of 2 quarters · filed 2023-08-07 | $823.30M 10-Q · filed 2022-11-07 | $943.00M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-06-30 | $330.90M 10-Q · filed 2023-08-07 | $496.00M 10-Q · filed 2023-08-07 | $615.70M derived: sum of 3 quarters · filed 2023-08-07 | $760.80M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $165.10M 10-Q · filed 2023-05-08 | $284.80M derived: sum of 2 quarters · filed 2023-05-08 | $429.90M derived: sum of 3 quarters · filed 2023-05-08 | $380.70M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $119.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $264.80M derived: sum of 2 quarters · filed 2023-02-27 | $215.60M derived: sum of 3 quarters · filed 2023-02-27 | $479.00M 10-K · filed 2023-02-27 |
| 2021-09-30 | $145.10M 10-Q · filed 2022-11-07 | $95.90M derived: sum of 2 quarters · filed 2022-11-07 | $359.30M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$49.20M 10-Q · filed 2022-08-08 | $214.20M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $263.40M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$325.80M 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $76.30M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |